Literature DB >> 30051419

Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripheral Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Nerves.

B M Cook1,2, K M Wozniak3, D A Proctor4, R B Bromberg4, Y Wu3, B S Slusher3, B A Littlefield5, M A Jordan1,4, L Wilson1,4, Stuart C Feinstein6,7.   

Abstract

The reversibility of chemotherapy-induced peripheral neuropathy (CIPN), a disabling and potentially permanent side effect of microtubule-targeting agents (MTAs), is becoming an increasingly important issue as treatment outcomes improve. The molecular mechanisms regulating the variability in time to onset, severity, and time to recovery from CIPN between the common MTAs paclitaxel and eribulin are unknown. Previously (Benbow et al. in Neurotox Res 29:299-313, 2016), we found that after 2 weeks of a maximum tolerated dose (MTD) in mice, paclitaxel treatment resulted in severe reductions in axon area density, higher frequency of myelin abnormalities, and increased numbers of Schwann cell nuclei in sciatic nerves. Biochemically, eribulin induced greater microtubule-stabilizing effects than paclitaxel. Here, we extended these comparative MTD studies to assess the recovery from these short-term effects of paclitaxel, eribulin, and a third MTA, ixabepilone, over the course of 6 months. Paclitaxel induced a persistent reduction in axon area density over the entire 6-month recovery period, unlike ixabepilone- or eribulin-treated animals. The abundance of myelin abnormalities rapidly declined after cessation of all drugs but recovered most slowly after paclitaxel treatment. Paclitaxel- and ixabepilone- but not eribulin-treated animals exhibited increased Schwann cell numbers during the recovery period. Tubulin composition and biochemistry rapidly returned from MTD-induced levels of α-tubulin, acetylated α-tubulin, and end-binding protein 1 to control levels following cessation of drug treatment. Taken together, sciatic nerve axons recovered more rapidly from morphological effects in eribulin- and ixabepilone-treated animals than in paclitaxel-treated animals and drug-induced increases in protein expression levels following paclitaxel and eribulin treatment were relatively transient.

Entities:  

Keywords:  Chemotherapy-induced peripheral neuropathy; Eribulin; Ixabepilone; Microtubules; Paclitaxel; Sciatic nerve

Mesh:

Substances:

Year:  2018        PMID: 30051419     DOI: 10.1007/s12640-018-9929-8

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  72 in total

Review 1.  Microtubule tip-interacting proteins: a view from both ends.

Authors:  Kai Jiang; Anna Akhmanova
Journal:  Curr Opin Cell Biol       Date:  2011-02       Impact factor: 8.382

2.  Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6.

Authors:  Yuliya Zilberman; Christoph Ballestrem; Letizia Carramusa; Ralph Mazitschek; Saadi Khochbin; Alexander Bershadsky
Journal:  J Cell Sci       Date:  2009-09-08       Impact factor: 5.285

3.  Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy.

Authors:  Dawn L Hershman; Louis H Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; Deborah Fuentes; Danielle Awad; Katherine D Crew
Journal:  Breast Cancer Res Treat       Date:  2010-12-03       Impact factor: 4.872

4.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Authors:  Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves
Journal:  Lancet       Date:  2011-03-02       Impact factor: 79.321

Review 5.  Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Authors:  Javier Cortes; Alberto J Montero; Stefan Glück
Journal:  Cancer Treat Rev       Date:  2011-05-08       Impact factor: 12.111

6.  Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Larry C Driver; Diane M Novy; Brian M Bruel; Deidre L Mooring; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

7.  Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.

Authors:  H Choy; W Akerley; H Safran; J Clark; V Rege; A Papa; M Glantz; Y Puthawala; C Soderberg; L Leone
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

8.  Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.

Authors:  Krystyna M Wozniak; Ying Wu; Mohamed H Farah; Bruce A Littlefield; Kenichi Nomoto; Barbara S Slusher
Journal:  Neurotox Res       Date:  2013-04-30       Impact factor: 3.911

9.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Authors:  Eva Thomas; Josep Tabernero; Monica Fornier; Pierfranco Conté; Pierre Fumoleau; Ana Lluch; Linda T Vahdat; Craig A Bunnell; Howard A Burris; Patrice Viens; José Baselga; Edgardo Rivera; Valentina Guarneri; Valerie Poulart; Judith Klimovsky; David Lebwohl; Miguel Martin
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

10.  Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.

Authors:  Linda T Vahdat; Agustin A Garcia; Charles Vogel; Christine Pellegrino; Deborah L Lindquist; Nicholas Iannotti; Prashanth Gopalakrishna; Joseph A Sparano
Journal:  Breast Cancer Res Treat       Date:  2013-07-23       Impact factor: 4.872

View more
  5 in total

Review 1.  Neurophysiopathological Aspects of Paclitaxel-induced Peripheral Neuropathy.

Authors:  Roberto Velasco-González; Ulises Coffeen
Journal:  Neurotox Res       Date:  2022-09-28       Impact factor: 3.978

Review 2.  Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy.

Authors:  Jordi Bruna; Paola Alberti; Aina Calls-Cobos; Martial Caillaud; M Imad Damaj; Xavier Navarro
Journal:  Exp Neurol       Date:  2019-12-15       Impact factor: 5.330

3.  Signaling pathways and gene co-expression modules associated with cytoskeleton and axon morphology in breast cancer survivors with chronic paclitaxel-induced peripheral neuropathy.

Authors:  Kord M Kober; Mark Schumacher; Yvette P Conley; Kimberly Topp; Melissa Mazor; Marilynn J Hammer; Steven M Paul; Jon D Levine; Christine Miaskowski
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

4.  Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.

Authors:  Naruto Taira; Kosuke Kashiwabara; Junji Tsurutani; Masahiro Kitada; Masato Takahashi; Hiroaki Kato; Yuichiro Kikawa; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Tsutomu Takashima; Tomohiko Aihara; Hirofumi Mukai; Fumikata Hara
Journal:  Breast Cancer       Date:  2021-09-07       Impact factor: 4.239

Review 5.  Mechanisms of Chemotherapy-Induced Neurotoxicity.

Authors:  Halina Was; Agata Borkowska; Ana Bagues; Longlong Tu; Julia Y H Liu; Zengbing Lu; John A Rudd; Kulmira Nurgali; Raquel Abalo
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.